Pfizer to pay Beam $300 million in gene-editing deal, amping up its mRNA ambitions

Pfizer is making a major push to leverage mRNA technology, on which its Covid-19 vaccine is based, to develop new vaccines and treatments.

The drug giant said Monday it will pay Beam Therapeutics, a Cambridge, Mass., startup founded by Harvard researcher David Liu, $300 million to spend four years developing treatments for three undisclosed rare genetic diseases affecting the liver, the muscles, and the central nervous system.

Read the rest…